Trials / Completed
CompletedNCT03011177
Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients
A Randomized, Open Label, Parallel-group, Non-inferiority, Active-controlled, Phase Ⅳ Study to Evaluate the Efficacy and Safety of Teneligliptin Versus Linagliptin in Type 2 Diabetes Mellitus Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Handok Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.
Detailed description
A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin | teneligliptin 20mg qd |
| DRUG | Linagliptin | linagliptin 5mg qd |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2018-09-01
- Completion
- 2018-09-01
- First posted
- 2017-01-05
- Last updated
- 2019-02-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03011177. Inclusion in this directory is not an endorsement.